Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials

@article{Xiang2017AdjunctiveMF,
  title={Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials},
  author={Ying-qiang Xiang and Wei Zheng and Shi-bin Wang and Xin-Hu Yang and Dong-Bin Cai and Chee H. Ng and Gabor S. Ungvari and Deanna L. Kelly and Weiping Xu and Yutao Xiang},
  journal={European Neuropsychopharmacology},
  year={2017},
  volume={27},
  pages={8-18}
}

Figures and Tables from this paper

Minocycline for Depressive Symptoms: a Meta-Analysis of Randomized, Double-Blinded, Placebo-Controlled Trials
TLDR
Minocycline appears to be effective and well-tolerated in ameliorating depressive symptoms in unipolar depression, and future large RCTs with sufficient duration are needed to confirm the positive effects of minocy Cline in treating depressive symptoms.
Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials
TLDR
This meta-analysis showed that adjunctive memantine appears to be an efficacious and safe treatment for improving negative symptoms and neurocognitive performance in schizophrenia.
Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis
TLDR
This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.
Adjunctive minocycline in schizophrenia: what one well-conducted study can tell us (and what it can’t)
TLDR
Minocycline has been proposed as treatment for negative symptoms in schizophrenia due to its neuroprotective and anti-inflammatory properties but negative results of a large RCT (BeneMin) have been recently published.
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
TLDR
The results of the study do not support the use of adjunctive minocycline for the treatment of negative or other symptoms of schizophrenia within 2–5 years of onset and more secure evidence of central inflammation is needed before further trials are conducted at other stages of psychosis.
...
...

References

SHOWING 1-10 OF 47 REFERENCES
Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial.
TLDR
This trial supports the effectiveness of minocycline as an adjuvant treatment with risperidone for treating negative symptoms of patients with schizophrenia.
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms
TLDR
Significant improvements with minocycline were seen in working memory, avolition, and anxiety/depressive symptoms in a chronic population with persistent symptoms in this 10-week, double-blind, placebo-controlled trial.
Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment
TLDR
The addition of minocycline to TAU early in the course of schizophrenia predominantly improves negative symptoms, and this is mediated by neuroprotective, anti-inflammatory or others actions.
A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.
TLDR
The findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia, which showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale).
Minocycline as Adjunctive Therapy for Schizophrenia: An Open-Label Study
TLDR
The results suggest that minocyCline may be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotics efficacy and for treating schizophrenia.
Clozapine versus typical neuroleptic medication for schizophrenia.
TLDR
Clozapine is found to be more acceptable in long-term treatment than conventional antipsychotic drugs and typical neuroleptic drugs for broad outcomes such as mortality, ability to work or suitability for discharge at the end of the study.
...
...